bromhexine

Bromhexine is an expectorant mucolytic agent which can be used in the treatment of respiratory disorders associated with excessive mucus or viscid.

Bromhexine hydrochloride (Bisolvon) is a mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus.

Bromhexine Impurity B reagent used in the preparation of Ambroxol and Bromhexine (B678600) metabolites Ambroxol EP Impurity E.

Bromhexine-d3 HCl is a deuterated compound of Bromhexine HCl. Bromhexine HCl has a CAS number of 611-75-6. Bromhexine hydrochloride is a mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus.

Ambroxol (NA-872) is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. It is the active ingredient of Mucosolvan, Lasolvan or Mucoangin. The substance is a mucoactive drug with several properties including secretolytic and secretomotoric actions that restore the physiological clearance mechanisms of the respiratory tract which play an important role in the body's natural defense mechanisms. It stimulates synthesis and release of surfactant by type II pneumocytes. Surfactants act as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents.

Ambroxol hydrochloride (Mucosolvan) is a metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.

Ambroxol-d5 is intended for use as an internal standard for the quantification of ambroxol by GC- or LC-MS. Ambroxol is an expectorant and active metabolite of bromhexine. It decreases short-circuit currents in electrically stimulated isolated canine tracheal epithelial cells when applied submucosally. Ambroxol decreases IL-13-induced production of mucin 5AC (MUC5AC) in primary human airway epithelial cells and inhibits IL-13-induced decreases in the mucociliary transport rate of endogenous particles in the same cells. Ambroxol increases phenol red secretion, a marker of expectorant activity, in mice when administered at doses of 30, 60, or 120 mg/kg. Formulations containing ambroxol have been used in the treatment of acute or chronic respiratory conditions.

Nesosteine sodium salt is an effective bronchitis inhibitor that enhances the rheology and production of bronchial mucus in rabbits. When administered via sulfuric acid nebulization in animals with induced bronchitis, this compound significantly reduces the viscosity of bronchial mucus and increases mucus production in healthy animals. It exhibits greater activity compared to other mucoregulatory drugs, such as Sobrerol, N-acetylcysteine, bromhexine, ambroxol, S-carboxymethylcysteine, and thiopropamine. Additionally, Nesosteine sodium salt reduces the total protein content in the airway bronchial mucus, including albumins and mucoproteins α1, α2, β, and γ.

Ambroxol acefylline, an active metabolite of the proagent Bromhexine, has potent expectorant effects and functions as a glucocerebrosidase (GCase) chaperone, increasing GCase activity. It induces lung autophagy and has potential applications in Parkinson's disease and neuronopathic Gaucher disease research [1][2].